Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALLAD+: Open-label Extension Study of Efgartigimod PH20 SC in Bullous Pemphigoid
jRCT2011230060Completed
- Sponsor
- argenx
- Start
- Feb 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of efgartigimod alfa in Bullous Pemphigoid (BP), sponsored by argenx. Primary endpoints: Incidence and severity of treatment-emergent AEs, SAEs, and AESIs and Rate of treatment discontinuation because of safety concerns. Started Feb 2024; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on jRCT2011230060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230060.